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Abstract 
 
Type II diabetes is a disease that begins as insulin resistance in the tissues of the body and over 
time, the insulin-producing β cells in the pancreas become so stressed that they cannot 
adequately produce insulin.  Decreased β cell functionality leads to states of hyperglycemia 
where blood glucose levels are dangerously high, leading to complications such as heart attack 
and stroke.  In order to develop treatments for this disease, the glucagon-like peptide-1 receptor 
(GLP-1R) has been identified as a medicinal target.  Studies of the binding of GLP-1R have 
taken many directions, including X-ray crystallography and computational modeling.  Also, 
peptide-based treatments for type II diabetes have been proposed and are in use.  However, small 
molecules can aid both fronts as treatments for type II diabetes and probes for small molecule 
active site exploration in GLP-1R.  One particular small molecule that interacts with GLP-1R is 
T-0632.  This molecule was originally developed for interacting with the cholecystokinin 
receptor, but it also binds well to GLP-1R.  Although an antagonist to GLP-1R, T-0632 can be 
used to study the small molecule binding site of GLP-1R to give insight into what small 
molecule structures could activate the receptor.  Our research focuses on synthesizing 
photolabile T-0632 derivatives to map the small molecule active site of GLP-1R with the help of 
our collaborators at the Mayo Clinic in Phoenix, AZ.  
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1.  Introduction 
1.1  Type II Diabetes 
Diabetes is a group of conditions related to high blood sugar levels.
1
  There are two main types 
of diabetes: type I and type II.  Type I diabetes is called insulin-dependent diabetes mellitus or 
juvenile-onset diabetes and develops when the insulin-producing β cells in the pancreas are 
irreversibly damaged.  A person with type I diabetes can produce little or no insulin and depends 
on treatments such as insulin injections.  Type II diabetes is also known as non-insulin-
dependent diabetes mellitus or adult-onset diabetes.
2
  In the United States alone, approximately 
29.1 million people have type II diabetes and it is estimated that as many as 8.1 million people 
may be undiagnosed.
3
  Most often, type II diabetes begins as an insulin-resistance disorder, 
where the muscle, liver, and fat cells in the body cannot use insulin properly.
1-2
  As the body’s 
requirement for insulin rises, the β cells lose their functionality due to long-term stress from 
producing insulin.
2
   
As a result of limited insulin and the body’s inability to use the insulin produced, sugar builds up 
in the blood in a state called hyperglycemia.
4
  Some common complications that arise from very 
high blood glucose levels are heart attack and stroke.
5
  There are many treatment options 
available for preventing problems associated with hyperglycemia.  Some of the most common 
types of medications to reduce blood glucose levels are dipeptidyl peptidase-IV (DPP-IV) 
inhibitors,  glucagon-like peptide-1 (GLP-1) receptor agonists,
6
 and both long-term and fast-
acting insulin.
7
  Although these medications are effective in reducing the risk of hyperglycemia, 
they can cause hypoglycemia, which is a state of dangerously low blood glucose levels.
6-7
  An 
understanding of type II diabetes at the molecular level will allow the design of more potent and 
effective treatment options with fewer side effects. 
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1.2  Type II Diabetes Treatment at a Molecular Level – GLP-1R 
 
Figure 1: Sequence of GLP-1R with tryptophan residues highlighted in grey (from Figure 1 in 
Wilmen et al.)
8
 
A particular receptor of interest involved in the body’s insulin pathways is the glucagon-like 
peptide 1 receptor (GLP-1R).  GLP-1R is part of the class B1 family of G-protein-coupled 
receptors.
9-11
  This class of receptors has may particular characteristics, including seven 
transmembrane alpha helices, three conserved disulfide bonds in the N-terminus, and structurally 
similar peptide hormone endogenous ligands.
10-11
  In the case of GLP-1R, its endogenous ligand, 
glucagon-like peptide 1 (GLP-1), binds to GLP-1R to activate the insulin-producing β cells in the 
pancreas to secrete insulin into the bloodstream via a cAMP-dependent chain of reactions.
11-13
  
When insulin levels rise, blood glucose levels drop,
13-14
 gastric emptying is delayed,
15
 and 
glucagon secretion is inhibited
15-16
 – all contributing to a feeling of satiety and causing a 
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decrease in food consumption.
15
  Thus, activation of GLP-1R has been identified as a potential 
treatment for type II diabetes.
17
   
1.3  Peptides as Treatments for Type II Diabetes 
Administration of the endogenous ligand of GLP-1R, the hormone GLP-1, has been explored as 
a treatment for type II diabetes.
18-19
  However, the enzyme dipeptidyl peptidase-IV (DPP-IV) can 
recognize active forms of GLP-1 and alter them so they become inactive.
20
  This issue led to the 
use of GLP-1 derivatives that were not deactivated by DPP-IV, such as glucose-dependent 
insulinotropic peptide (GIP).  Yet GIP does not have as many favorable effects in the body, such 
as delayed gastric emptying, inhibited glucagon secretion, and reduced food uptake.
21
  Another 
peptide-based agonist and structural probe of GLP-1R is the compound Extendin 4 (Ex4),
22-23
 
which was originally extracted from Gila monster (H suspectum) saliva.  This peptide is 
marketed in the form of the drug Exenatide.
22
 
 
Figure 2: Gila monster (H suspectum) – the saliva of this reptile was the first source of Ex4 
(from the Zoo Atlanta website)
24
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Although peptide-based treatments are effective once administered,
25
 many of these medications 
must be injected.  The difficulty and discomfort associated with injections could affect the extent 
to which a medication is used properly.  Using small molecules instead of peptides as treatments 
for type II diabetes could result in a drug that is orally administrable, and could increase proper 
usage of medications.
10
  However, despite the ongoing efforts of researchers worldwide,  the 
structure of the GLP-1R binding site is still not fully understood.
26
  Additionally, many 
nonpeptide ligands do not bind to the endogenous ligand active site and instead bind to allosteric 
binding sites or sites that cover only some of the endogenous binding site.
10
  Thus, an 
understanding of the structure and binding of GLP-1R in its entirety is necessary in order to 
effectively design small-molecule targets to activate GLP-1R. 
1.4  X-Ray Crystallography and Computational Modeling to Explore the GLP-1R Active Site 
Knowing the amino acid sequence of any protein does not provide enough information to know 
its functions in vivo and the three-dimensional structure of its active site.  In order to create a 
complete picture of the active site of GLP-1R, many analytical methods are needed.  Some of the 
techniques that have been employed to study GLP-1R include x-ray crystallography and 
computer modeling. 
X-ray crystallography is one of the most powerful analytical methods to study proteins and other 
large biomolecules.  Despite the method’s limitations for studying biomolecules within our 
current understanding of chemistry, such as the need for large sample quantities, difficulties in 
getting molecules to crystallize, and changes in conformation in the solid state versus in aqueous 
solution,
27-28
 x-ray crystallography can provide crucial information about the structure of GLP-
1R.  Runge et al. crystallized the N-terminus extracellular region of GLP-1R with a selenium 
derivative of the exogenous peptide ligand Exendin-4 (Ex4) with a resolution of 2.2 Å.
11
  With 
10 
 
this resolution, almost all atoms but hydrogen atoms can be identified.
27
  The apo- and holo-form 
crystal structures elucidated the positions and conformations of many amino acids as well as 
details about the first step in the two-step process of peptide ligand binding.  The authors also 
posit that the structure of the complex and the ligand-receptor interactions were not altered by 
crystal packing.
11
 
 
Figure 3: X-ray crystallography structures of the holo-form of the binding N-terminus of GLP-
1R in complex with Ex4 (helix in red, β-strands in yellow, loops in green, Ex4 in blue) (from 
Figure 1A in Runge et al.)
11
 
In addition to x-ray crystallography, more information about the active site structure of GLP-1R 
has been obtained by computational modeling studies.  Lin and Wang used software that 
incorporates homology modeling, molecular docking, and long-time molecular dynamics 
simulations in a cell-membrane-type environment to model the three-dimensional structure of 
GLP-1R as well as the binding modes for some of the endogenous agonists of the receptor.  They 
11 
 
found two distinct conformations of GLP-1R and the two corresponding motions the receptor 
goes through in the transition between the occupied holo-form and the unoccupied apo-form.
17
  
 
Figure 4: Software-generated images of  the apo-form of GLP-1R (left) and activated  holo-form 
of GLP-1R complexed with GLP-1 (right) (from Figure 13 in Lin and Wang)
17
 
1.5  Using Small Molecules to Probe the Structure of the Small Molecule GLP-1R Active Site 
The methods mentioned above mostly provide insight into the structure of the endogenous 
binding site.  In order to explore allosteric or other binding regions of GLP-1R, small molecules 
can be used to probe other binding regions even if they are not agonists.  The information 
gathered from these small probe molecules can then be used to design molecules that activate 
GLP-1R. 
A molecule that has previously been used to explore GLP-1R is called T-0632 [sodium (S)-3-[1-
(2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinyl)-carbonyl]amino-6-methoxy-2-oxo-1-H-
indole]propanoate].  This molecule was developed by researchers in the Lead Optimization 
12 
 
Research Laboratory in Japan to study the cholecystokinin receptor
10, 29-30
 and then, because of 
the similarities in structure between the cholecystokinin receptor and GLP-1R, T-0632 was used 
by Tibaduiza, Chen, and Beinborn to study allosteric binding in GLP-1R.
10, 15
 
 
Figure 5: The molecule T-0632 developed by Taniguchi et al. and used by Tibaduiza et al. to 
study allosteric binding sites in GLP-1R 
In 1996, Taniguchi, Yazaki, Endo, and Nagasaki studied the action of T-0632 in vitro and in vivo 
to investigate the interactions between iodine-125-labeled cholecystokinin ([
125
I]CCK-8) and the 
cholecystokinin (CCKA) receptor.
29-30
  CCK acts both in the central nervous system and in areas 
of the gastrointestinal tract including the pancreas.  Taniguchi et al. studied the effects of this 
hormone in CCKA receptors found in rat pancreas in their in vitro studies.  They found that T-
0632 competitively inhibited the binding of [
125
I]CCK-8 to the CCKA receptor. Thus, it was 
suggested that T-0632 reversibly, selectively, and effectively inhibits activity of the CCKA 
receptor.
29
  When they continued their studies in vivo, they compared T-0632 to other 
compounds known to inhibit the CCKA receptor, such as L-364,718 and loxiglumide, and studied 
the extent to which the receptor was inhibited.  T-0632, when administered intravenously, was 
13 
 
just as potent as L-364,718 at inhibiting the CCKA receptor.  When administered 
intraduodenally, T-0632 was only 2-fold weaker in inhibiting the CCKA receptor, similarly to 
loxiglumide and better than L-364,718, which experienced a 20-fold decrease in inhibitory 
activity.  These results were promising since T-0632 has potential to be an orally available drug 
with similar effects to other available drugs without the risks associated with the other 
medications, such as gallstones, and without the need for injections.
30
 
After this success by Taniguchi et al. and the similarity in structure between the CCKA receptor 
and GLP-1R, Tibaduiza, Chen, and Beinborn used T-0632 to study GLP-1R binding.  They 
found that T-0632 does bind to GLP-1R and allosterically inhibits activity.  Although T-0632 is 
an antagonist and it is essential for GLP-1R to be activated for effective type II diabetes 
treatments, Taniguchi et al. were able to study binding as well as the affinity T-0632 had for the 
receptor.  By expressing mutant forms of human and rat GLP-1R, they found that tryptophan 33 
was the key binding residue present in human GLP-1R and absent in rat GLP-1R that resulted in 
high binding affinities of T-0632.  The data collected were valuable steps toward developing 
small molecule drugs to activate GLP-1R as a potential type II diabetes treatment.
15
   
1.6  Furthering Our Understanding of the Small Molecule Active Site Structure in GLP-1R – 
Photoaffinity Labeling 
To gather additional information of the small molecule active site of GLP-1R, it is desirable to 
map the amino acids within the active site and how they are oriented.  One method to accomplish 
these goals, and the method employed in this project, is photoaffinity labeling.
31
  This technique 
to study biological molecules, also called photoimmobilization, was developed over thirty years 
ago and has recently increased in use due to more efficient chromophores and more sensitive 
analytical techniques.  As illustrated in Figure 6 below, the regioselectively-labeled ligand first 
14 
 
binds to the active site of the molecule.  The ligand-protein complex is then irradiated with light 
which activates the photolabile group
32
 and causes covalent attachment to the nearest amino acid 
residue.  The biological molecule with the attached ligand is then fragmented and the fragments 
are analyzed to determine the amino acid at the place of attachment.  By using many derivatives 
of the labeled ligand, key amino acid residues in the active site can be identified.
33-34
  
Understanding the topography of the active site in this way is an effective strategy to develop 
pharmaceuticals to act on that active site.
34
 
 
Figure 6: General mechanism for photolabile group function in active site topography 
determination 
Photolabile groups are stable under most biological conditions – barring light of the wavelength 
required for activation and covalent attachment.
32
  Other desirable properties of these groups 
include: an excited state lifetime shorter than the dissociation of the ligand-receptor interaction 
but long enough to allow for covalent linkage, clear photochemical reactivity to allow for 
predictable and controllable covalent bond formation, and an excited state that reacts with 
functional groups present on the molecule of study.
34
 
Photolabile groups can be incorporated into native and non-native ligands of a biomolecule to 
explore both the native active site and other sites of interaction by non-native ligands, such as 
pharmaceuticals.
31, 34
  A few examples of photolabile functional groups are tetrafluorophenyl 
15 
 
azides, trifluoromethylphenyl diazirines, and benzophenone moieties.
34
  Although these groups 
have different chemistries, they function in similar ways as illustrated in Figure 6 above.  The 
azide functional group operates via the specific chemical mechanism shown below in Figure 7. 
 
Figure 7: Proposed mechanistic paths for the action of a photolabile azide group in the 4-
position (our target position) of T-0632 (adapted from Figure 5b in Dorman and Prestwich)
34
 
In the case of GLP-1, photoaffinity labeling studies have been conducted using GLP-1 analogs 
that inserted photolabile p-Benzoyl-L-phenylalanine (Bpa) in place of various amino acids to 
determine spatial relationships within the active site.
33, 35
  However, Bpa labeled GLP-1 is not the 
only way to study the active site of GLP-1R. 
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1.7  Project Goals 
There are many aromatic components of T-0632 that can be used to make photolabile 
derivatives.  One of these components is the isoquinoline ring system, highlighted in red below.  
This moiety within T-0632 is the focus of this project. 
 
Figure 8: Structure of T-0632 with the isoquinoline moiety highlighted in red 
The goals of this project are to: synthesize 3-methylisoquinoline starting material; mono-iodinate 
3-methylisoquinoline; oxidize the methyl of 3-methylisoquinoline; combine the iodination and 
oxidation procedures; combine the iodinated and oxidized isoquinoline derivative with the rest of 
the T-0632 molecule to make a full T-0632 derivative; send the T-0632 derivative to our 
collaborators at the Mayo Clinic, Phoenix, AZ, for preliminary biological testing; and synthesize 
and send the azido T-0632 derivative if the iodinated derivative binds to GLP-1R. 
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2.  Results and Discussion 
2.1  Synthesis of 3-Methylisoquinoline 
 
Figure 9: 3-Methylisoquinoline with labeled aromatic positions 
With the goal of making a full T-0632 derivative with a photolabile isoquinoline portion, our 
synthesis began with making the 3-methylisoquinoline.  The 3-position methyl is critical in 
forming the secondary amide that connects the isoquinoline portion of T-0632 to the rest of the 
molecule.   
 
Scheme 1: Reaction scheme for the synthesis of 3-methylisoquinoline (procedure from Bellizzi et 
al.)
36
 
The synthesis consisted of two steps.  The first step combined benzylamine and 1,1-
dimethoxypropan-2-one with sodium triacetoxyborohydride to form N-benzyl-1,1-
dimethoxypropan-2-one.  In the proposed mechanism below, the nitrogen of benzylamine 
attaches to the carbonyl carbon of 1,1-dimethoxypropan-2-one.  The purpose of the gentle 
borohydride is to reduce the proposed imine intermediate.  Once N-benzyl-1,1-
dimethoxypropan-2-one is formed, chlorosulfonic acid is used in the second step of the reaction 
18 
 
to remove a methoxy group of the acetal and promote a ring closure reaction to form the 
nitrogen-containing ring.  Then, the chlorosulfonic acid is attacked by the nitrogen which enables 
an E1-type elimination reaction to oxidize the nitrogen-containing ring aromatic to give the final 
product: 3-methylisoquinoline. 
 
Figure 10: Proposed mechanism for the synthesis of 3-methylisoquinoline 
19 
 
We confirmed the structure of our final product using GC-MS, 
1
HNMR, and 
13
CNMR (see 
Appendices 1-4 and Figure 11 below).  The GC data showed one peak, with the molecular ion 
peak in the corresponding MS reading as m/z = 143, which is the expected mass of 
methylisoquinoline.  
1
HNMR confirmed the isomeric structure of our product.  The aromatic 
region showed two singlets, two doublets, and two triplets with slight shoulders, each integrating 
for one proton.  The isomeric structure of methylisoquinoline that corresponds with that splitting 
pattern is 3-methylisoquinoline.  The 
13
CNMR confirmed that the final product had one benzylic 
carbon and nine aromatic carbons. 
 
Figure 11: δ7.44-8.02 aromatic region of the 1HNMR for 3-methylisoquinoline – note the singlet 
at approximately δ7.5 corresponding to the 4-position proton 
20 
 
2.2  Synthesis of 4-Iodo-3-Methylisoquinoline 
After the successful synthesis of the 3-methylisoquinoline starting material, we could begin 
functionalization reactions.  To iodinate the starting material, we first attempted a reaction using 
N-iodosuccinimide (NIS) in glacial acetic acid and sulfuric acid to attempt an electrophilic 
aromatic substitution reaction.  However, even with reactions attempted at room temperature and 
two higher temperatures with an excess of NIS, this reaction did not produce sufficient quantities 
of any desired products.  We believe that these reactions were unsuccessful because the iodine of 
NIS is insufficiently electrophilic to promote electrophilic aromatic substitution, even when NIS 
is strongly protonated.   
We then tried was an iodic acid iodination that was purported to work with isoquinolines and 
particularly 3-methylisoquinoline.  It was also proposed in the literature that it would give 
iodination at the 4-position.
37
 
 
Scheme 2: Reaction scheme for the synthesis of 4-iodo-3-methylisoquinoline (procedure adapted 
from Edinger
37
) 
The reaction mixture from this iodic acid iodination was analyzed using GC-MS, 
1
HNMR, and 
13
CNMR (see Appendices 5-8 and Figure 12 below).  The GC had many peaks, but one of them 
had a molecular ion peak of m/z = 269 corresponding to an iodinated 3-methylisoquinoline.  
Upon separation via flash chromatography, we were able to perform NMR studies on the 
21 
 
iodinated product.  The 
1
HNMR, when compared with the one for 3-methylisoquinoline, has a 
missing singlet in the aromatic region that was seen in the starting material at δ7.5 due to the 4-
position aromatic proton next to the methyl group.  The 
13
CNMR also showed one of the 
aromatic carbons that was previously at around δ120 had shifted to around δ100, which is 
consistent with an aromatic carbon bonded to an iodine.  Thus, we had evidence that we had 
synthesized 4-iodo-3-methylisoquinoline. 
 
Figure 12: Top – δ7.54-8.12 aromatic region 1HNMRof 4-iodo3-methylisoquinoline – note the 
absence of a singlet around δ7.54; bottom – comparison of 13CNMR data for 3-
methylisoquinoline (left) and 4-iodo-3-methylisoquinoline (right) – note the change in peak 
position between δ120 for 3-methylisoquinoline and δ100 for 4-iodo-3-methylisoquinoline 
22 
 
We propose that this reaction uses iodic acid, which is an oxidizing acid, rather than any other 
acid because of its ability to oxidize I2 and produce I
+
.  The I
+
 can then add to the isoquinoline at 
the 4-position and a proton is eliminated to produce 4-iodo-3-methylisoquinoline. 
 
Figure 13: Proposed mechanism for the iodic acid iodination reaction 
The placement of the iodide on the 4-position is exciting because previous work with 
isoquinoline derivatives in the Haines Lab had yet to produce an isoquinoline derivative with the 
iodide on the nitrogen-containing ring.  This new position of iodination has the potential to give 
us access to unexplored regions of the GLP-1R binding site. 
2.3  Synthesis of Benzoyl Peroxide-Catalyzed Free-Radical Bromination of 3-
Methylisoquinoline 
The next step in the functionalization of 3-methylisoquinoline was to oxidize the methyl.  We 
decided to pursue bromination reactions as a first step toward the eventual goal of oxidation.  
The first few bromination attempts were free-radical bromination reactions, but without a 
catalyst to help produce that radical.  The result was mostly unreacted starting material.  In the 
next set of reactions, we introduced benzoyl peroxide as our catalyst.  We tried a reaction with 
benzoyl peroxide and used bromobenzene as the solvent.  However, we only added 0.1 
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equivalents of NBS with respect to the 3-methylisoquinoline starting material, and so much of 
the 3-methylisoquinoline remained unreacted.  In the next reaction, we used 1.1 equivalents of 
NBS with the benzoyl peroxide catalyst and bromobenzene as the solvent, but the reaction did 
not yield any recognizable products possibly due to interference of the bromobenzene since it 
was difficult to remove.  Our last and most successful attempt at free-radical bromination used 
carbon tetrachloride as the solvent, and this finally gave us the reactivity necessary to produce 
sufficient quantities of brominated products. 
 
Scheme 3: Reaction scheme for the free-radical bromination of 3-methylisoquinoline (procedure 
from Chun Wong et al.)
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The GC showed many peaks (see Appendix 9), and upon analysis with MS, four of the peaks had 
evidence of bromine atoms present on the 3-methylisoquinoline (see Appendices 10-13).  Two of 
the peaks had masses that suggested one bromide and two of the peaks had masses that suggested 
two bromides.   
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Figure 14: Proposed mechanism for BPO free-radical bromination reaction (for di-brominated 
products, the process continues with another methyl hydrogen) 
We attempted a separation of the reaction mixture using flash chromatography, but we only 
eluted two brominated products.  Subsequent NMR analysis suggested that those products that 
eluted were 1) a di-brominated product that had both bromines on the methyl group (see 
Appendices 23-24) and 2) a mono-brominated product that was brominated at the 4-position (see 
Appendix 25).  Even when we used the maximum recommended concentration of ethanol in 
ethyl acetate that would not degrade the silica gel on the column, the other products would not 
elute.  We hypothesize that the other two products were 3) mono-brominated on the methyl and 
4) di-brominated with one on the methyl and one on the 4-position.  We believe that the mono-
brominated methyl group was susceptible to nucleophilic attack by the hydroxyl groups in silica 
gel.  The oxygens displaced the bromides resulting in covalent attachment to the column 
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material.  The di-brominated product that had both bromides on the methyl was probably too 
bulky to have the oxygens in the silica gel displace even one of the bromides. 
2.4  Methoxide Displacement of  Bromide on Free-Radical Bromination of 3-
Methylisoquinoline Reaction Mixture 
After the bromination procedure was established, we tried displacement reactions to oxidize the 
methyl.  Our first attempt consisted of combining the unpurified reaction mixture from a free-
radical bromination with sodium bicarbonate in water and dimethylformamide.  This procedure 
was not strong enough to displace the bromides from any of the brominated compounds.  We 
then made the reaction conditions more aggressive by using ethanol and sodium acetate, but, 
again, displacement did not occur. A reaction we tried with sodium hydroxide in dioxane did 
convert the methyl into an aldehyde (see Appendices 20-22), but the aldehyde is too de-
activating to then perform an iodic acid iodination.  The aldehyde would limit the reactions we 
could do in other steps on the way to a full isoquinoline derivative, so we decided to search for 
another displacement procedure. 
The displacement conditions that worked best for the crude reaction mixture from the free-
radical bromination consisted of dissolving approximately two equivalents of sodium hydroxide 
(with respect to the original 3-methylisoquinoline starting material) in heated methanol and then 
adding this warm solution to the unpurified free-radical bromination reaction mixture.  After 
letting this reaction boil at reflux for 30 minutes, it was analyzed via GC-MS (see Appendices 
14-15). 
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Scheme 4: Reaction scheme for the methoxide ion displacement of the reaction mixture from the 
free-radical bromination of 3-methylisoquinoline 
The GC showed many peaks, and the MS data showed a molecular ion peak of m/z = 173, which 
is consistent with the desired methoxylated product.  We believe the methoxide created by de-
protonated methanol displaced the bromide of the 3-bromomethylisoquinoline (depicted above in 
Scheme 4).   
Since the GC-MS data showed promise, we decided to iodinate this product. 
2.5  Combination of Iodination and Displacement Procedures 
Before we had the chance to iodinate the methoxylated product, we had tried other reactions to 
obtain an iodinated and oxidized isoquinoline derivative.  A free-radical bromination of 4-iodo-
3-methylisoquinoline resulted in the bromide preferentially displacing the iodide.  We 
hypothesize that since the carbon attached to the iodide has increased electron density (as seen in 
the 
13
CNMR of 4-iodo-3-methylisoquinoline), the bromonium ions seek that electron density and 
the iodinium leaves as a cation.  We also attempted many trials of a selenium (IV) dioxide 
oxidation reaction that, depending on the particular trial run, produced unrecognizable products 
or reduced the 4-iodo-3-methylisoquinoline.  We are not sure of the mechanism of this reaction 
and decided to look for other synthetic methods to obtain oxidized products.  Although we were 
fairly certain it would not work, we performed an iodic acid iodination reaction on isoquinoline-
3-carboxylic acid.  We believed that the carboxylic acid would be too electron-withdrawing to 
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adequately promote electrophilic aromatic substitution in the iodination reaction, and we were 
proven correct upon analysis via GC-MS.  There were many peaks in the GC, and none of them 
were decipherable except for unreacted isoquinoline-3-carboxylic acid. 
The combination of iodination and oxidation procedures that did produce identifiable and useful 
products was the iodic acid iodination of the crude methoxylated product.   
 
Scheme 5: Reaction scheme for the iodic acid iodination of the crude methoxylated product 
The reaction mixture was analyzed via GC-MS (see Appendices 16-19).  The GC showed many 
peaks, but three of the peaks looked promising when examining the MS spectra.  Two peaks had 
a molecular ion minus a methyl group peak at m/z = 284, which is consistent with the iodinated 
and methoxylated product shown in Scheme 5 above.  Another peak had a molecular ion peak of 
m/z = 285, which is consistent with the hydrolysis of the methoxy group to a hydroxyl.   
Separation of the reaction mixture was attempted with flash chromatography, but the scale of the 
reaction was so small that it was difficult to separate and we only obtained roughly pure samples 
of our target compounds that were not pure enough for NMR analysis.  Therefore, we do not 
know the isomeric structure of the compounds that were synthesized. 
To make the separation of products more feasible, we started from the synthesis of 3-
methylisoquinoline and tried to optimize at every step of the reaction procedure.  The free-
radical bromination reaction was run for 8 hours – which was long enough to produce products 
we wanted but not so long that unidentifiable and useless side products were formed.  At the 
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methoxide displacement step, we used a smaller volume of methanol to concentrate the sodium 
hydroxide and, thus, the resulting methoxide ions.  However, after this step of the reaction 
procedure, the yields of the methoxylated product were so low that they were hardly detectable 
in GC-MS and we were not able to complete the series of reactions. 
3.  Conclusions and Future Work 
3.1  Conclusions 
In summary, we successfully synthesized 3-methylisoquinoline, 4-iodo-3-methylisoquinoline, 
methyl-brominated 3-methylisoquinoline, methoxylated 3-methylisoquinoline, and iodinated and 
methoxylated 3-methylisoquinoline.  We have confirmed the isomeric structures of 3-
methylisoquinoline, 4-iodo-3-methylisoquinoline, and the brominated products via GC-MS and 
NMR.  For the methoxylated 3-methylisoquinoline and iodinated and methoxylated 3-
methylisoquinoline, we only have GC-MS data to confirm masses of structures. 
3.2  Future Work 
The most immediate steps in furthering this project include: optimizing conditions for the 
methoxide displacement reaction to obtain higher yields of the desired products; purifying the 
reaction mixture from the methoxide displacement reaction to perform 
1
HNMR and 
13
CNMR 
and make conclusions on the structures of the products; running the iodic acid iodination 
procedure on the purified methoxylated and alcohol products; purifying the reaction mixture 
from the iodination step to perform 
1
HNMR and 
13
CNMR to determine the isomeric structure of 
the iodinated and oxidized product; oxidizing the iodinated methoxylated and alcohol products to 
the carboxylic acid; purifying and connecting the carboxylic acid product to the rest of the T-
0632 molecule and sending the full derivative to the Mayo Clinic in Phoenix, AZ, for 
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preliminary biological testing and binding studies; and synthesizing the azide derivative of the 
iodinated derivative if the iodinated compound binds to GLP-1R to send to the Mayo Clinic for 
further biological testing and binding studies. 
4.  Experimental 
4.1  Rayanne Method Parameters Used for All GC-MS Data Acquisition 
Oven initial temperature: 120 ºC; maximum oven temperature: 325 ºC.  Initial time: 3.60 
minutes; equilibration time: 0.50 minutes.  Ramp 1: 20.00 ºC per minute until 325 ºC at 7.00 
minutes.  Ramp 2: 0.00 ºC per minute until end.  Total run time: 20.85 minutes.  Column: 
capillary column Agilent 19091S-433, HP-5MS, 0.25 mm * 30 m * 0.25 µ; mode: constant flow; 
initial flow: 1.0 mL per minute; average velocity: 38 cm per second.  Injection volume: 1.0 µL.  
Solvent delay: 3.60 minutes.  Low mass: 50.0; high mass: 600.0; threshold: 150. 
4.2  Successful Reactions 
4.2.1  3-Methylisoquinoline Synthesis
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Benzylamine (9.18 mL, 84.0 mmol) and 1,1-dimethoxypropan-2-one (9.95 mL, 84.0 mmol) were 
added to dichloromethane (350 mL) at room temperature.  Sodium triacetoxyborohydride (25 g, 
118 mmol) was added to the reaction mixture in one portion.  The reaction was stirred at room 
temperature overnight.  The reaction mixture was then diluted with 2.5% sodium bicarbonate 
(250 mL) and mixed for 30 minutes, becoming biphasic.  The organic layer was discarded.  The 
aqueous layer was basified to pH 14 using concentrated sodium hydroxide.  The basified 
aqueous solution was washed three times with ethyl acetate and the organic layers were kept and 
combined.  Then, the resulting solution was washed with 5% sodium chloride solution three 
times.  The organic layers were combined and dried over sodium sulfate.  The resulting solution 
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was evaporated to a yellow oil, which was found to be N-benzyl-1,1-dimethoxypropan-2-one.  
The oil (2.62 g, 12.5 mmol) was added dropwise to chlorosulfonic acid (8.35 mL, 125 mmol) 
over ice.  A few milliliters of dichloromethane was used to rinse the oil from its reaction flask 
and the oil dissolved in dichloromethane was also added to the chlorosulfonic acid flask over ice.  
The reaction mixture was placed over boiling water for 5 minutes with a condenser to evaporate 
the solvent used to rinse the N-benzyl-1,1-dimethoxypropan-2-one out of its previous flask while 
not letting any water vapor enter the flask before the reaction mixture was fully heated.  Then, 
the reaction mixture was placed in the boiling water for 10 minutes without a condenser to allow 
methanol, a side-product of the reaction, to evaporate out of the flask and drive the reaction 
forward.  After cooling, the reaction mixture was quenched with ice and then basified to pH 14 
with concentrated sodium hydroxide.  The mixture was washed with dichloromethane three 
times.  The organic layers were combined and dried using magnesium sulfate.  The resulting 
solution was evaporated to solid 3-methylisoquinoline (average percent yield: 2-5%) and the 
structure was confirmed with GC-MS and NMR.  GC-MS Spectrum (Appendix 1): Retention 
time: approximately 5.8 minutes.  M
+
: m/z = 143; M
+
 - CH3 : m/z = 128.  
1
HNMR in CDCl3 
(Appendices 2-3):  δ2.73 (s, 3H, methyl), δ7.28 (s, CHCl3), δ7.51 (s, 1H, 4-position H), δ7.53-
7.56 (t, 1H, 7-position H), δ7.65-7,68 (t, 1H, 8-position H), δ7.75-7.76 (d, 1H, 6-position H), 
δ7.95-7.96 (d, 1H, 9-position H), δ9.21 (s, 1H, 11-position H).  13CNMR in CDCl3 (Appendix 4): 
δ24.21 (methyl), δ76.61-77.46 (m, CDCl3), δ118.47 (4-position C), δ125.9, δ126.27, δ126.84, 
δ127.51, δ130.29, δ136.55, δ151.6, δ151.95. 
4.2.2  4-Iodo-3-Methylisoquinoline Synthesis
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3-Methlisoquinoline (0.05 g, 0.35 mmol), iodine (0.09 g, 0.35 mmol), iodic acid (0.02 g, 0.12 
mmol), and water (3 mL) were added together and heated at reflux for 6 hours.  After the 
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reaction mixture cooled, it was extracted and washed three times with dichloromethane.  The 
organic layers were washed with a saturated sodium thiosulfate solution until the color went 
from deep purple to light yellow.  The organic layers were collected, combined, and dried with 
sodium sulfate.  The resulting solution was evaporated to a solid.  The product was then purified 
via flash chromatography to isolate 4-iodo-3-methylisoquinoline (average yield: 30-40%) and the 
structure was confirmed via GC-MS and NMR.  GC-MS Spectrum (Appendix 5): Retention time: 
approximately 9.13 minutes.  M
+
: m/z = 269; I: m/z = 127; M
+
 - I: m/z = 142.  
1
HNMR in CDCl3 
(Appendices 6-7): δ 1.65 (s, impurity), δ2.99 (s, 3H, methyl), δ7.26 (s, CHCl3), δ7.57-7.60 (t, 
1H, 7-position H), δ7.73-7.76 (t, 1H, 8-position H), δ7.87-7.88 (d, 1H, 6-position H), δ8.07-8.09 
(d, 1H, 9-position H), δ9.03 (s, 1H, 11-position H).  13CNMR in CDCl3 (Appendix 8): δ30.25 
(methyl), δ76.76-77.27 (m, CDCl3), δ99.17 (4-position C), δ127.12, δ127.55, δ127.84, δ131.00, 
δ131.86, δ138.30, δ151.74, δ154.92. 
4.2.3  Free-Radical Bromination of 3-Methylisoquinoline
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3-Methylisoquinoline (0.24 g, 1.68 mmol), N-bromosuccinimide (0.3286 g, 1.85 mmol), benzoyl 
peroxide (0.0030 g, 8.39 µmol), and carbon tetrachloride (approximately 25 mL) were added 
together and heated at reflux for approximately 8 hours.  Once the reaction mixture was cooled, 
it was partitioned between dichloromethane and water.  The organic layers were collected and 
dried with sodium sulfate.  GC-MS analysis showed a mixture of mostly mono-brominated and 
di-brominated products.  GC-MS Spectrum (Appendices 9-13): Retention times: mono-bromo-3-
methylisoquinoline #1 at 8.17 minutes; mono-bromo-3-methylisoquinoline #2 at 8.79 minutes; 
di-bromo-3-methylisoquinoline #1 at 10.13 minutes; di-bromo-3-methylisoquinoline #2 at 10.44 
minutes.  Mono-bromo-3-methylisoquinoline #1 – M+: 1:1 ratio m/z = 221:223; M+ - Br: m/z = 
142.  Mono-bromo-3-methylisoquinoline #2 – M+: 1:1 ratio m/z = 221:223; M+ - Br: m/z = 142.  
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Di-bromo-3-methylisoquinoline #1 – M+: 1:2:1 m/z = 299:301:303; M+ - Br: 1:1 m/z = 220:222.  
Di-bromo-3-methylisoquinoline #2 – M+: 1:2:1 m/z = 299:301:303; M+ - Br: 1:1 m/z = 220:222; 
M
+
 - 2Br: m/z = 141. 
4.2.4  Methoxide Displacement of  Bromide on Free-Radical Bromination of 3-
Methylisoquinoline Reaction Mixture 
Sodium hydroxide (0.0144g, 0.36 mmol, ~2 eq with respect to the original 3-methylisoquinoline 
starting material for this set of reactions) was added to methanol (30 mL) while stirring and the 
mixture was heated until all the sodium hydroxide was dissolved.  The methanol/sodium 
hydroxide solution was added to the free-radical bromination of 3-methylisoquinoline reaction 
mixture and stirred on reflux for 30 minutes.  After the reaction mixture was cool, the methanol 
was evaporated.  The resulting material was dissolved in dichloromethane and washed with 
water and the organic layers were dried with sodium sulfate.  The GC-MS data showed a mixture 
of products, with one of the products having masses corresponding with the addition of a 
methoxy group to 3-methylisoquinoline and another of the products having a masses 
corresponding to the addition of an alcohol group to 3-methylisoquinoline.  GC-MS Spectrum 
(Appendices 14-15): Retention time: 7.76 minutes.  M
+
: m/z = 173; M
+
 - CH2 – OCH3: m/z = 
128. 
4.2.5  Iodic Acid Iodination of Methoxide Displacement Reaction Mixture
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The methoxide displacement reaction mixture (started with 0.0207 g, 0.14 mmol 3-
methylisoquinoline), iodine (0.0381 g, 0.15 mmol), iodic acid (0.0097 g, 0.05 mmol), and water 
(5 mL) were added together and heated under reflux while stirring for 4 hours.  After the reaction 
mixture was cooled, it was partitioned between dichloromethane and water.  The organic layers 
were then washed with a saturated sodium thiosulfate solution until pale yellow in color.  The 
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organic layers were dried with sodium sulfate.  The GC-MS data suggested there was a small 
amount of iodinated methoxylated 3-methylisoquinoline and an iodinated 3-methylisoquinoline 
with a hydroxyl group.  Flash chromatography was not successful in fully separating the desired 
product due to small quantities of desired product and the possibility of solvent left in the 
samplet.  GC-MS Spectrum (Appendices 16-19): Retention times: iodinated and methoxylated 
compound #1 at 10.32 minutes; iodinated and methoxylated compound #2 at 10.87 minutes; 
iodinated alcohol compound at approximately 11.44 minutes.  Iodinated and methoxylated 
compound #1 – M+ - CH3: m/z = 284; I: m/z = 127.  Iodinated and methoxylated compound #2 – 
M
+
 - CH3: m/z = 284; I: m/z = 127.  Iodinated alcohol compound – M
+
: m/z = 285; I: m/z = 127. 
4.3  Unsuccessful Reactions 
4.3.1  NIS Iodination of 3-Methylisoquinoline 
3-Methylisoquinoline (0.05 g, 0.35 mmol), glacial acetic acid (0.1 mL, 1.83 mmol), and sulfuric 
acid (2 drops, 1.88 mmol) were combined and put on ice for 10 minutes.  Then, N-
iodosuccinimide (0.09 g, 0.40 mmol) was measured and added to the reaction mixture in the 
dark.  The round-bottom flask was taken off the ice, wrapped in aluminum foil, and covered with 
a rubber septum.  The reaction mixture was stirred while the reaction vessel was flushed with 
nitrogen gas for 30 minutes.  Then, the reaction mixture was then left to stir for another 6 hours.  
The reaction mixture was then partitioned between dichloromethane and water.  The organic 
layers were then washed with a saturated sodium thiosulfate solution until pale yellow.  The 
organic layers were combined and dried with sodium sulfate.  The GC-MS showed mostly 
unreacted 3-methylisoquinoline and very small quantities of an iodinated compound.  The 
reaction mixture was re-used as the starting material in a second iodination attempt with the 
same reaction procedure except the reaction mixture was heated to 60 ºC for 24 hours instead of 
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stirring at room temperature for 6 hours.  The reaction mixture was worked-up and dried in the 
same fashion as previously.  The GC-MS data showed that, again, the 3-methylisoquinoline 
remained mostly unreacted and there was very little iodinated product.  This reaction mixture 
was re-used in a third iodination attempt with the same reaction procedure except that 2 
equivalents (0.18 g, 0.80 mmol) of N-iodosuccinimide were added after the temperature of the 
reaction mixture reached 60 ºC and then the temperature was increased to 90 ºC while the flask 
was flushed with nitrogen gas for 30 minutes.  After the nitrogen gas flow was stopped, the 
reaction stirred at 90 ºC for 3 hours.  Then, the reaction flask was lifted off the heating mantle 
and another 2 equivalents of N-iodosuccinimide (0.18 g, 0.80 mmol) were added and put back on 
the mantle and heated to 90 ºC while nitrogen gas was flushed through the reaction mixture for 
30 minutes.  The temperature was kept at 90 ºC for another 24 hours.  The reaction mixture was 
cooled and worked-up and dried in the same manner as previously described.  The GC-MS data 
for this reaction still showed mostly unreacted 3-methylisoquinoline and very little iodinated 
product. 
4.3.2  NBS Bromination of 3-Methylisoquinoline 
3-Methylisoquinoline (0.05 g, 0.35 mmol), N-bromosuccinimide (0.12 g, 0.67 mmol), and 
dichloromethane (2 mL) were added together and stirred for 4 hours.  The reaction mixture was 
then washed with a potassium carbonate solution and water.  The organic layers were dried with 
sodium sulfate.  GC-MS data showed that most of the 3-methylisoquinoline remained unreacted 
and very few brominated products were formed.   
4.3.3  Free-Radical Bromination of 3-Methylisoquinoline – Attempt 1 
3-Methylisoquinoline (0.08 g, 0.56 mmol), N-bromosuccinimide (0.01 g, 0.06 mmol), benzoyl 
peroxide (0.0008 g, 3.31 µmol), and bromobenzene (3 mL) were combined and heated to 80 ºC 
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with stirring for 8 hours.  Once the reaction mixture was cooled, it was washed with a potassium 
carbonate solution and then with water.  The organic layer was dried with sodium sulfate.  The 
GC-MS data from this reaction mixture showed mostly unreacted 3-methylisoquinoline and very 
few brominated products.   
4.3.4  Free-Radical Bromination of 3-Methylisoquinoline – Attempt 2 
3-Methylisoquinoline (0.05 g, 0.35 mmol), N-bromosuccinimide (0.0685 g, 0.39 mmol), benzoyl 
peroxide (0.0004 g, 1.75 µmol), and bromobenzene (3 mL) were combined and heated while 
stirring to 80 ºC overnight.  Once the reaction mixture was cooled, it was rinsed with a potassium 
carbonate solution and water.  The organic layer was dried with sodium sulfate.  The GC-MS 
data from this reaction mixture showed mostly unreacted 3-methylisoquinoline and some 
brominated products.   
4.3.5  Displacement of Bromide(s) with Sodium Bicarbonate, Water, and Dimethylformamide  
The solvent in which the brominated product in 4.2.4 (above) was dissolved in was evaporated.  
Then, an aqueous sodium bicarbonate solution and dimethylformamide were added to the 
evaporated reaction mixture.  The reaction stirred for 48 hours.  The reaction mixture was then 
partitioned between dichloromethane and water.  The organic layer was washed again with water 
to remove as much dimethylformamide as possible.  The organic layer of the reaction mixture 
was dried with sodium sulfate.  GC-MS data showed unreacted brominated peaks with no 
recognizable displacement peaks. 
4.3.6  Displacement of Bromide(s) with Ethanol/Sodium Acetate Solution 
The solvent was removed from the reaction mixture as described in 4.2.5 (above).  A saturated 
solution of ethanol and sodium acetate was added to the evaporated reaction mixture and stirred 
36 
 
for 48 hours.  Then, the reaction mixture was partitioned between dichloromethane and water.  
The organic layer was dried with sodium sulfate.  The GC-MS data showed no recognizable 
peaks, not even unreacted brominated peaks.   
4.3.7  Displacement of Bromides on Dibromo-3-Methylisoquinoline with Dioxane/Sodium 
Hydroxide Solution 
After running a column on a free-radical bromination of 3-methylisoquinoline reaction mixture 
and azeotroping the fractions with acetonitrile to remove water, we were able to obtain a very 
small quantity of fairly pure di-bromo-3-methylisoquinoline (Br on methyl) (
1
HNMR in 
Appendix 23).  After evaporating the CDCl3, dioxane (5 mL) and a sodium hydroxide solution (1 
mL, 5% solution) were added to the evaporated reaction mixture and stirred vigorously for 1 
hour.  The solution was neutralized to pH 7 with hydrochloric acid (2 M).  The reaction mixture 
was evaporated slightly to remove some of the dioxane and then partitioned between 
dichloromethane and water.  The organic layer was dried with sodium sulfate.  The product, 
according to GC-MS and NMR data, was unreacted starting material.  Next, the dioxane/sodium 
hydroxide procedure was repeated except the reaction mixture was heated to 70 ºC for 4 hours.  
After the reaction mixture was cooled, it was neutralized to pH 6 with hydrochloric acid (2 M).  
The mixture was partitioned between dichloromethane and water and the resulting organic layer 
was dried with sodium sulfate.  The GC-MS and NMR data suggested the main product was an 
aldehyde.  This reaction was not pursued further since the aldehyde is de-activating to 
electrophilic aromatic substitution and would limit possible reaction orders for synthesizing a full 
iodinated and oxidized 3-methylisoquinoline product.  GC-MS Spectrum (Appendices 20-21): 
Retention time: 7.55 minutes.  M
+
: m/z = 157; M
+ 
- O: m/z = 141 M
+
 - COH: m/z = 128.  
1
HNMR in CDCl3 (Appendix 22): Aldehyde peak: δ10.28. 
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4.3.8  Free-Radical Bromination of 4-Iodo-3-Methylisoquinoline
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4-Iodo-3-methylisoquinoline (0.0261 g, 0.0097 mmol), N-bromosuccinimide (0.0190 g, 0.011 
mmol), benzoyl peroxide (0.0001 g, 0.485 µmol), and carbon tetrachloride (2 mL) were 
combined and stirred under reflux for 8 hours.  Once the reaction mixture was cooled, it was 
partitioned between dichloromethane and water.  The organic layer was dried with sodium 
sulfate.  The GC-MS data showed very high amounts of mono-brominated 3-methylisoquinoline 
(without an iodide) and a small amount of unreacted 4-iodo-3-methylisoquinoline among small 
quantities of other side products.  This suggests the bromide preferentially displaced the iodide. 
4.3.9  Selenium (IV) Dioxide Oxidation of 4-Iodo-3-Methylisoquinoline
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4-Iodo-3-methylisoquinoline (0.3007 g, 1.02 mmol), selenium (IV) dioxide (1.6914 g, 15.2 
mmol), and ethanol (10 mL) were combined and stirred under reflux for 24 hours.  The reaction 
mixture was run through a celite pad to remove any solid selenium.  The mixture was evaporated 
to remove the ethanol.  The sticky solid was then diluted in dichloromethane and washed with 
water.  The organic layers were dried with sodium sulfate.  The GC-MS data showed almost pure 
unreacted 4-iodo-3-methylisoquinoline.  The reaction was re-run as previously described 
assuming the same amount of 4-iodo-3-methylisoquinoline except with butanol (1 mL) in place 
of ethanol.  The reaction mixture was run through a celite pad and evaporated, worked-up, and 
dried as previously described.  The GC-MS data showed detectable quantities of 3-
methylisoquinoline, suggesting the reaction reduced the 4-iodo-3-methylisoquinoline instead of 
oxidizing it.  The 
1
HNMR (in CDCl3) of the reaction mixture was not like either 4-iodo-3-
methylisoquinoline or 3-methylisoquinoline and so the reaction’s product(s) were 
unrecognizable.  To check if the carboxylic acid was produced, a saturated sodium thiosulfate 
solution was added to the aqueous layers from the work up and acidified to pH 3 with 
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hydrochloric acid (5%).  The aqueous solution was partitioned between dichloromethane and the 
organic layer was dried with sodium sulfate.  The GC-MS data showed small amounts of 4-iodo-
3-methylisoquinoline and 3-methylisoquinoline and then many overlapping and unrecognizable 
peaks.  The 
1
HNMR (in CDCl3) confirmed that the aldehyde was not produced.  The organic 
layer material from the original work up was then washed with sodium thiosulfate and acidified 
to pH 2 with hydrochloric acid (2 M).  The resulting organic layer was dried using sodium 
sulfate.  The GC-MS and 
1
HNMR (in CDCl3) showed unrecognizable products, but a column 
was run on the reaction mixture, but none of the fractions had GC-MS or 
1
HNMR data that made 
sense with any expected products.   
4.3.10  Iodic Acid Iodination of Isoquinoline-3-Carboxylic Acid
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Isoquinoline-3-carboxylic acid (0.0500 g, 0.29 mmol), iodine (0.0733 g, 0.29 mmol), iodic acid 
(0.0169 g, 0.01 mmol), and water (5 mL) were combined and stirred on reflux for 3 hours.  After 
the reaction mixture was cooled, it was extracted with dichloromethane and water.  The organic 
layer was washed with a sodium thiosulfate solution until pale yellow and dried with sodium 
sulfate.  The GC-MS showed no recognizable products. 
4.3.11  Methoxide Displacement of Bromide on Free-Radical Bromination of 3-
Methylisoquinoline Reaction Mixture – Optimization Attempt 
After another free-radical bromination of 3-methylisoquinoline, another methoxide displacement 
reaction was attempted.  This time, sodium hydroxide (0.1344 g, 2 eq with respect to 3-
methylisoquinoline starting material) and a reduced amount of methanol (50 mL) were heated 
and stirred together until the sodium hydroxide dissolved.  The methanol/sodium hydroxide 
solution was added to the free-radical bromination reaction mixture and stirred under reflux for 
30 minutes.  Once the reaction mixture was cooled, the methanol was evaporated and the 
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resulting material was partitioned between dichloromethane and water.  The organic layers were 
dried with sodium sulfate.  The GC-MS showed very low yields of the methoxylated product 
with this attempted optimization. 
4.4  Other Experimental Work 
4.4.1  Melting Point Determination of Benzoyl Peroxide 
Using a Mel-Temp II instrument from Laboratory Devices, USA, the melting point of the 
benzyol peroxide was determined to ensure the compound had not degraded.  The expected 
melting range of benzoyl peroxide is 103 – 106 ºC.40  The melting range of the benzoyl peroxide 
was 102.5 – 104.5 ºC, confirming the product had not degraded. 
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